A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 145 participants.

Also called NCT03267108

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 145 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03267108
Other papers using this trial's data
  • Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-controlled Trial Annals of the American Thoracic Society, 2024-12 DOI, PubMed 39141673

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03267108. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-14 (actual); primary completion 2023-06-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension
Acronym
REBUILD
Condition
Pulmonary Fibrosis
Intervention (Combination product)
INOpulse®
Intervention (Combination product)
Placebo
Intervention (Combination product)
Open Label Extension
Lead sponsor
Bellerophon Pulse Technologies (class: industry)

Record details

Record id
cardio:ct-nct03267108
Content hash
1be7dc26791748a336b3674a2310acd97dd1e794bf666648a4080c577304a8d2